© 2024 Access Intelligence, LLC - All Rights Reserved
PAGES
CATEGORIES
Current POWER Magazine Issue
We are first in your inbox with the most important news in the industry?keeping you smarter and one-step ahead in this ever-changing and competitive market.
Start your free subscription) 2020 Access Intelligence, LLC - All Rights Reserved
Successful drug development hinges on multimillion-dollar decisions about mechanism of action, safety, dosage, and patient response. While genomics, transcriptomics, and proteomics are well-established tools in the drug development arsenal, these tools stop short of providing a real-time, definitive representation of the clinical phenotype.
Derek Solum, Ph.D., Associate Director, Product Development at United Therapeutics, and Brian Keppler, Ph.D., Director, Discovery and Translational Sciences, Metabolon, Inc., share how metabolomics has helped United Therapeutics enhance its multi-omics platform and improve decision-making across all phases of drug development.
In this talk you’ll learn:
Offered Free by: Metabolon
See All Resources from: Metabolon